Literature DB >> 20739216

Antiviral treatment for severe EBV infections in apparently immunocompetent patients.

Petros I Rafailidis1, Michael N Mavros, Anastasios Kapaskelis, Matthew E Falagas.   

Abstract

BACKGROUND: Infectious mononucleosis usually runs a mild self-limiting course. Complications arise rarely and when so, corticosteroids are the mainstay of their treatment. The role of antivirals in the management of severe EBV infections is debatable.
METHODS: We sought to review the usage of antivirals for severe EBV infection in apparently immunocompetent patients. For this reason a search in PubMed and Scopus was performed for the time period from 1982 to 2009.
RESULTS: 45 patients with severe manifestations of infectious mononucleosis received antivirals (as an adjunct to steroids in 26 of them). Specifically 21 patients with CNS involvement (meningoencephalitis, cerebellitis), 4 with peripheral nervous system involvement (Guillain-Barré, myeloradiculitis, facial nerve palsy), 5 with hepatitis and 15 with other afflictions (including adult respiratory distress syndrome, thrombocytopenia, aplastic anemia, acute renal failure, ulcerations, myocarditis, and frosted branch vasculitis) received antiviral medications. Thirty-nine out of these 45 patients had a favourable outcome (27 were cured and 12 showed clinical improvement) while 6 patients died. The most commonly prescribed antiviral regimen was acyclovir monotherapy (35 patients). Three patients received combinations of acyclovir with other antivirals and 1 received famciclovir. Three patients received ganciclovir monotherapy, 1 ganciclovir plus foscarnet, 1 foscarnet and 1 vidarabine.
CONCLUSION: The available data derive from case reports and case series and thus the deduction of conclusions regarding the effect, if any, of antiviral treatment is debatable. However, physicians may consider using antiviral agents in severe manifestations of EBV infections in immunocompetent patients as an adjunct to steroid treatment.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739216     DOI: 10.1016/j.jcv.2010.07.008

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  19 in total

1.  Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.

Authors:  Natacha Coen; Sophie Duraffour; Lieve Naesens; Marcela Krecmerová; Joost Van den Oord; Robert Snoeck; Graciela Andrei
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Necrotic sore throat, tender lymphadenopathies, hepatitis and activated lymphocytes in circulating blood as a clinical presentation of severe infectious mononucleosis.

Authors:  Claire Tissot; Christian Chidiac; Florence Ader; Tristan Ferry
Journal:  BMJ Case Rep       Date:  2014-11-20

3.  [Fulminant EBV meningoencephalitis : Good clinical outcome in a young, immunocompetent female].

Authors:  F Derler; S Seidel; D Bengel
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

4.  Severe EBV hepatitis treated with valganciclovir.

Authors:  R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi
Journal:  Infection       Date:  2012-07-27       Impact factor: 3.553

5.  A case of fulminant Epstein-Barr virus encephalitis in an immune-competent adult.

Authors:  Marvyn T Koning; Tessa Brik; Rogier Hagenbeek; Ido van den Wijngaard
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

6.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

7.  Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Authors:  Natacha Coen; Sophie Duraffour; Kazuhiro Haraguchi; Jan Balzarini; Joost J van den Oord; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

8.  Mortality in schizophrenia: clinical and serological predictors.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Jennifer Schroeder; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2013-08-13       Impact factor: 9.306

Review 9.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

10.  Visual detection and evaluation of latent and lytic gene expression during Epstein-Barr virus infection using one-step reverse transcription loop-mediated isothermal amplification.

Authors:  Xiaoying Liu; Jingfeng Tang; Man Wang; Qiang Ma; Yefu Wang
Journal:  Int J Mol Sci       Date:  2013-12-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.